<DOC>
	<DOCNO>NCT00865098</DOCNO>
	<brief_summary>This study conduct Japanese newly diagnose locally advanced SCCHN patient order assess tolerability feasibility Cetuximab plus concomitant boost radiotherapy ( RT ) regimen ( study treatment ) safety profile ( i.e . AEs : adverse event ) . In addition , efficacy ( i.e . anti-tumor effect ) study treatment also evaluate .</brief_summary>
	<brief_title>Study Cetuximab With Concomitant-boost Radiotherapy Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma Head Neck ( SCCHN )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . The patient pathologically proven squamous cell carcinoma arise oropharynx , hypopharynx , larynx . 2 . The patient confirm Epidermal Growth Factor Receptor express tumor specimen immunohistochemistry . 3 . The patient stage III IV disease ( Unio Internationalis Contra Cancrum / International Union Cancer TumorLymph NodesMetastases classification ) expect survival ≥ 12 month . 4 . The patient least bidimensionally measurable disease . 5 . The patient medically suitable withstand course definitive radiation therapy . 6 . The patient age ≥ 20 year old inform consent 7 . The patient 's Karnofsky performance status ≥ 60 8 . Hemoglobin ≥ 9g/dL 9 . Neutrophil ≥ 1500/mm^3 10 . Platelet ≥ 100,000/mm^3 11 . Total Bilirubin ≤ 1.5 mg/dL 12 . Aspartate Aminotransferase ≤ 2 x upper limit normal 13 . Alanine Aminotransferase ≤ 2 x upper limit normal 14 . Serum creatinine ≤ 1.5 mg/dL 15 . Serum calcium concentration : within normality 16 . The patient eligible disease free previously treat malignancy great three year . 17 . The patient agree use effective contraception procreative potential exists . 18 . The patient give sign informed consent 19 . The patient Japanese Japanese citizenship 1 . The patient evidence distant metastatic disease . The patient metastatic disease document Magnetic Resonance Imaging head neck , Computed Tomography chest abdomen exclude . 2 . The patient squamous cell carcinoma arise nasopharynx oral cavity . 3 . The patient receive prior systemic chemotherapy within last three year . 4 . The patient undergone previous surgery tumor study biopsy . 5 . The patient receive prior radiation therapy head neck . 6 . The patient 's radiation therapy consider part postoperative regimen follow primary surgical resection . 7 . The patient pregnant breast feeding . 8 . The patient receive prior Cetuximab murine monoclonal antibody ( include chimeric antibody ) therapy history severe hypersensitivity component Cetuximab solution Injection . 9 . The patient medical psychological condition would permit patient complete study sign inform consent ( include drug abuse ) . 10 . The patient uncontrolled diabetes mellitus , malignant hypertension , liver failure . 11 . The patient suffer pulmonary fibrosis , acute pulmonary disorder , interstitial pneumonia . 12 . The patient active infection ( infection require intravenous antibacterial , antifungus , antiviral agent ) , know declared Human Immunodeficiency Virus infection . 13 . The patient clinically relevant coronary artery disease history myocardial infarction last 12 month high risk uncontrolled arrhythmia uncontrolled cardiac insufficiency 14 . The patient dental disease require incision drainage . 15 . The patient active multiple cancer ( exclude skin cancer except melanoma , carcinoma situ cervix digestive tract ) last 3 year . 16 . The patient receive investigational medication within 30 day study entry .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Newly diagnose locally advanced squamous cell carcinoma head neck ( SCCHN )</keyword>
</DOC>